Consensus Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-05-17 am EDT			5-day change	1st Jan Change
1.3 ^EUR	0.00%		-7.80%	-28.18%

May. 15	Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents	CI
Jan. 25	Oncodesign Precision Medicine: fundraising on the horizon	CF

Evolution of the average Target Price on Oncodesign Precision Medicine

Price target over the last 5 years

History of analyst recommendation changes

633b26b14660e1785e52e511.l6rvtCPp5MW09VZZnva3ZSzJmgNavmTayDZmZ7LE3xA.7-Ta3WDZsqvBuDUh2qTEK1mfym4t1jWUp28MEvCxi3jPzqPXdNDV8vmhHw~a9e4996913c62191c14a704c84b130e5

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.3 EUR

Average target price

2.48 EUR

Spread / Average Target

+90.77%

High Price Target

2.66 EUR

Spread / Highest target

+104.62%

Low Price Target

2.3 EUR

Spread / Lowest Target

+76.92%

Consensus detail

Consensus revision (last 18 months)

Ratings for Oncodesign Precision Medicine

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar